Brief: Ono Pharmaceutical Enters Drug Discovery Collaboration & Option Agreement With Shattuck Labs
14/02/2024 10:32
Feb 14 (Reuters) - Ono Pharmaceutical 4528.T
* ONO ENTERS INTO A DRUG DISCOVERY COLLABORATION AND OPTION
AGREEMENT WITH SHATTUCK LABS TO GENERATE BIFUNCTIONAL FUSION
PROTEINS
* ONO PHARMACEUTICAL: WILL PAY TO SHATTUCK A TOTAL OF $227
MILLION, AS WELL AS TIERED ROYALTIES BASED ON NET SALES
Source text for Eikon: ID:nPnbmksdqa
Further company coverage: STTK.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on ONO PHARMACEUTICAL
See all newsBrief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
Bristol Myers sues Amgen over proposed Opdivo biosimilar (updated)
Bristol Myers sues Amgen over proposed Opdivo biosimilar
Brief: UK's MHRA Says Vimseltinib Approved For Use In Adults To Treat Tenosynovial Giant Cell Tumours